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Abstract: Denileukin diftitox (Ontak®) is indicated for the treatment of patients with persistent 
or recurrent cutaneous T-cell lymphoma (CTCL), a rare lymphoproliferative disorder of the 
skin. Denileukin diftitox was the first fusion protein toxin approved for the treatment of a human 
disease. This fusion protein toxin combines the IL2 protein with diphtheria toxin, and targets the 
CD25 subunit of the IL2 receptor, resulting in the unique delivery of a cytocidal agent to CD-25 
bearing T-cells. Historically, immunotherapy targeting malignant T-cells including monoclonal 
antibodies has been largely ineffective as cytocidal agents compared to immunotherapy directed 
against B-cells such as rituximab. This review will summarize the development of denileukin 
diftitox, its proposed mechanism of action, the pivotal clinical trials that led to its FDA approval, 
the improvements in quality of life, and the common toxicities experienced during the treatment 
of patients with CTCL. CTCL is often a chronic progressive lymphoma requiring the sequential 
use of treatments such as retinoids, traditional chemotherapy, or biological response modifiers. 
The incorporation of the immunotoxin denileukin diftitox into the sequential or combinatorial 
treatment of CTCL will also be addressed.
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Introduction
Cutaneous T-cell lymphomas (CTCL) account for roughly 3% of non-Hodgkin’s lym-
phoma (NHL) and are a heterogenous group of disorders characterized by clonal accu-
mulation of malignant CD4+ or CD8+ T-lymphocytes in the skin. According to a recent 
review of the SEER database and other registries, the incidence of CTCL is on the rise; 
approximately 6.4 per million persons will be diagnosed with CTCL each year.1
Mycosis fungoides (MF) and its leukemic variant, Sézary syndrome (SS), make 
up the majority of CTCL. Treatment algorithms have been developed for MF and 
SS and include combined or sequential therapies with multiple skin-directed as well 
as systemic agents.2 The NCCN and EORTC also have developed guidelines in the 
management of MF and SS. Decisions in initial or subsequent therapies such as skin-
directed therapy, radiation therapy, photopheresis, anti-neoplastic therapies, biologic 
therapies, or combined-modality treatment incorporate the disease stage, overall prog-
nosis, and quality-of life of the patient. For early-stage patients in whom remission is 
likely, the goal of therapy is to avoid long-term treatment-related toxicities; for patients 
with aggressive disease, approaches often include skin-directed as well as systemic 
therapies, including biologic or targeted therapy, and chemotherapy.
Staging of patients with MF and SS is essential both for its prognostic value and for 
decisions in management. The most commonly used staging system for MF/SS is based  Cancer Management and Research 2010:2 54
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on a tumor-node-metastasis-blood (TNMB) classification 
(Table 1).3 When MF is grouped by stage, patients with 
patch-plaque disease (stages IA, IB, and IIA) have an excel-
lent survival of more than 12 years; those with tumors or 
erythroderma (stages IIB/III) have a median survival of 
approximately 4 years; however, those with stage IV which 
includes patients with lymph node or visceral involvement, 
the median survival is less than 3 years.4 Similarly, SS has 
a median survival of less than 3 years.5,6 Kim et al showed 
that advanced age, T stage, and presence of extracutaneous 
disease correlated with a reduction in survival.7
Many patients die not from their disease, but the infec-
tious complications they develop, likely due to impaired 
immunity as well as from immunosuppressive effects of 
systemic therapies. One unique feature of this disease is 
that as the malignant T-cell clone expands, it does so at the 
expense of normal T-cells, creating an immunodeficiency in 
numbers of functional T-cells, as well as decreased production 
of TH1-type cytokines, and decreased NK cell activity.8 An 
important treatment paradigm is to introduce treatments that 
do not cause further immune suppression.
Denileukin diftitox (Ontak®; Eisai Inc.) is a biological 
therapeutic agent that is essentially a fusion protein toxin. 
A fusion protein toxin combines a targeting ligand such as 
a growth factor with a cytocidal moiety such as a plant or 
bacterial toxin. Denileukin diftitox uses a truncated diphthe-
ria toxin (DAB389) as the toxophore and this is fused to the 
full-length sequence of the IL2 protein. The IL2 moiety of 
the molecule directs the fusion toxin to cells bearing IL2R. 
Once bound to the IL2R, denileukin diftitox is internalized 
via receptor-mediated endocytosis in an acidified vesicle. 
Upon internalization and acidification, denileukin diftitox 
is proteolytically cleaved within the endosomes to liberate 
the enzymatically active portion of the diphtheria toxin. 
The fragment of diphtheria toxin is translocated across the 
endosomal membrane into the cytosol where it inhibits pro-
tein synthesis via ADP-ribosylation of elongation factor-2, 
ultimately resulting in cell death.9,10
The story of the birth of denileukin diftitox is an inter-
esting one, and it is worthwhile to review its development. 
Denileukin diftitox was born out of the ongoing discovery 
of IL2 and its receptors, and novel bioengineering.
History of IL2, IL2R, and anti-Tac
Since the cloning of the “autocrine T-cell growth factor”, 
IL2, in 1983, the IL2 receptor (IL2R) has been the subject 
of major investigation. Targeting of IL2R has subsequently 
been explored for its therapeutic potential as well as to help 
elucidate signal transduction pathways. We know now that 
the IL2R is a complex comprised by three parts: the alpha 
chain (CD25) which is required for high affinity binding, 
the beta chain (CD122) which participates in IL2 and IL15 
signal transduction, and the common gamma chain (CD132) 
which participates in downstream signal transduction of IL2 
and other cytokines.11–14
The generation of an anti-CD25 (anti-Tac) antibody 
has helped identify populations of cells where IL2R is 
expressed.15 In a normal subject, the IL2R is expressed 
mostly at a low level in less than 5% of normal circulating 
peripheral blood mononuclear cells (PBMC). However, the 
Table 1 Staging system for mycosis fungoides/Sézary syndrome based on a tumor-node-metastasis-blood classification
N M
T1: limited  
patch/plaque  
(10% BSA)






  N0: nodes  




  N1: nodes enlarged,  
  histologically uninvolved
M0 iiA
iiiB
  N2–3: nodes  
  clinically normal (N2)  
  or enlarged (N3),  
  histologically involved
M0 ivA
  N0–3: visceral  
  involvement
M1 ivB
  B0 Absence of significant peripheral blood Sézary cells
  B1 Low tumor burden that does not meet the criteria of B2 cells
  B2 Significant peripheral blood 1000/µL Sézary cells with positive clone
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greatest level of expression of CD25 is seen in the setting 
of T-cell malignancies such as cutaneous T-cell lymphoma, 
and adult T-cell leukemia. It is also highly expressed in 
hairy cell leukemia, Hodgkin’s disease, as well as some 
B-cell NHLs and histiocytic proliferations. Such observa-
tions are the basis for therapies that target IL2R-expressing 
cells. Indeed, high- or intermediate affinity IL2R isoforms 
are expressed in at least 50% of CTCL and 25% to 50% of 
B-cell non-Hodgkin’s lymphomas when tissue is examined 
by flow cytometry, and thus make the IL2R an attractive 
target for therapy.16
In 1995 Sakaguchi et al discovered that the high affinity 
IL2 receptor alpha chain was a reliable cell surface marker 
for regulatory T-cells (Tregs).17 CD4+ CD25+ cells were found 
to be anergic, failing to proliferate when stimulated by anti-
CD3 antibodies. They also suppressed the growth of CD4+ 
CD25– T-cells in vitro, as well as an admixture of conventional 
T-cells. Interestingly, although IL2 was required for their 
growth and survival, Tregs did not produce IL2 themselves.18 
Since CTCL is considered by some to be a malignant pro-
liferation of T-regs,19 the rationale behind targeting CD25 is 
even more robust.
Abnormalities of IL2R were also detected in autoimmune 
diseases such as rheumatoid arthritis, systemic lupus erythe-
matosus, aplastic anemia, and insulin-dependent diabetes. 
Increased expression of  CD25 was also detected in the serum 
of patients during solid organ allograft rejection, and in those 
with graft-versus-host disease (GVHD). Since the cloning of 
the IL2R receptor, work has been done to exploit the receptor 
as a target for therapy in T-cell malignancies, GVHD, and 
other autoimmune diseases.
Daclizumab is a humanized anti-Tac monoclonal anti-
body that has been tested in leukemia and lymphoma. In cell 
lines, it was thought that daclizumab blocked the interaction 
of IL2 and its receptor resulting in cytokine-deprivation-
mediated apoptotic cell death.20 Additionally, based on in vivo 
data from mouse models, it was thought that daclizumab also 
exerted an effect through an FcR receptor mechanism.21
Clinical trials using daclizumab in adult T-cell leukemia 
and lymphoma (ATL) was associated with partial responses 
predominantly in patients with smoldering or chronic ATL. 
Responding patients were hypothesized to have a blockage 
of the IL2–IL2R autocrine pathway.
Unfortunately, unlike other therapeutic monoclonal 
antibodies used in the treatment of human malignancies, 
daclizumab did not seem to have strong cytocidal activity. 
Therefore, other strategies were needed to make use of IL2R 
targeting in T-cell malignancies.
The IL2R-diphtheria toxin fusion 
protein: DAB486-IL2
In order to target the delivery of a cytocidal moiety to IL2R-
bearing cells, human IL2 was fused to truncated diphtheria 
toxin (DT). Unlike daclizumab (anti-Tac), which is a mAb 
directed against the CD25 component of the receptor, 
DAB486-IL2 contained the full-length sequence of IL2 as 
the ligand for the IL2R. The original fusion protein toxin 
used a fragment of DT containing methionine plus the first 
485 amino acids of DT resulting in the molecule DAB486-
IL2.9,22,23 While this molecule had clinical activity (1 com-
plete response, 2 partial responses, out of 18 patients), the 
maximum tolerated dose (MTD) was only 0.1 mg/kg/day, due 
to transaminase elevations.24 Five of 18 patients experienced 
fever associated with administration of the fusion protein 
toxin that responded to acetaminophen. The anti-tumor effect 
of DAB486-IL2 did not correlate with pre- or post-treatment 
antibodies to DT, DAB486-IL2, or IL2.
Denileukin diftitox (DAB 389-IL2)
Modifications were made to DAB 486-IL2 by removing 
97 amino acids from the native part of the toxin containing 
the disulfide bond, resulting in an increase in half-life and 
tolerance in animals. This resulted in a 5-fold greater affinity 
for IL2R and a 10-fold increase in potency.25,26 The resulting 
DAB389-IL2 fusion protein toxin is otherwise known as 
denileukin diftitox.
Denileukin diftitox binds to IL2R in the same way as IL2 
because it contains the full-length sequence of IL2. This opti-
mized fusion protein toxin binds to a high- or intermediate-
affinity receptor.27,28 Intermediate affinity receptors have 
beta (CD122) and gamma (CD132) subunits and bind IL2 
with Kd ∼10–9, and high-affinity receptors have the addition 
of the alpha (CD25) subunit and bind IL2 with Kd ∼10–11. 
Once denileukin diftitox binds to IL2R, this molecule is 
internalized into the cell where the truncated diphtheria 
toxin is cleaved off, liberated into the cytosol, and induces 
cell death by causing apoptosis.
A phase I clinical trial using DAB389-IL2 in patients with 
lymphomas expressing IL2R (CD25 or CD122) resulted in 
an MTD of 27 µg/kg/day.25 Unlike with the first generation 
fusion protein toxin, changes in liver function tests were not 
dose-limiting. The dose-limiting toxicities that were seen 
included asthenia, fever, nausea and vomiting. In addition, 
some of the CTCL patients who were treated in this trial 
exhibited signs and symptoms of capillary leak syndrome 
with edema, hypotension and hypoalbuminemia. Again, the  Cancer Management and Research 2010:2 56
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presence of antibodies to DT, DAB389-IL2, or IL2 pre- and 
post-treatment did not prevent treatment responses. The 
half-life of DAB 389-IL2 was found to be 72 minutes with 
monophasic clearance, and there was no dose accumulation 
with repeated doses of the drug.
In this trial, 35 patients had CTCL (30 MF, 4 large cell 
CTCL, and 1 cutaneous PTCL), and most were heavily pre-
treated. Of the 35 CTCL patients, 4 (11%) had a complete 
response, and 8 (24%) had a partial response. The median 
time to response was 2 months and the duration response 
ranged from 2 to 39+ weeks (median 10 months). There 
was no obvious correlation with the expression of CD122 
or CD132.25
In another phase I/II trial using DAB 389-IL2 that 
enrolled a more homogenous group of 35 patients with 
MF, a dose and schedule of DAB 389-IL2 given over 
5 consecutive days of a 21-day cycle was explored. Thirteen 
patients (37%) achieved an objective response, including a 
complete response in 5 patients (14%). Complete response 
was achieved in patients with extensive erythroderma and 
tumor-stage mycosis fungoides.29
A smaller trial of 4 heavily pre-treated CTCL patients 
who received either 9 (1 patient) or 18 (3 patients) µg/kg/day 
of DAB 389-IL2 for 5 days of a 21-day cycle showed 
striking results.30 One patient achieved a complete patho-
logical response, and another patient had a complete clinical 
response, and the other 2 patients had partial responses. 
Similar to prior trials, the duration of response ranged from 
5 to 11+ months. There was significant improvement in the 
symptoms and quality of life in these patients.
These trials formed the basis of the pivotal phase III 
trial of denileukin diftitox.31 This randomized, blinded, mul-
ticenter, parallel group study was designed to evaluate the 
efficacy, safety, and pharmacokinetics of two doses of deni-
leukin diftitox in patients with previously treated, advanced 
or refractory CTCL. The inclusion criteria required that 
patients have 20% of lymphocytes within the skin biopsy 
stain positive for CD25. Patients were randomized to receive 
either denileukin diftitox 9 or 18 µg/kg/day administered 
on 5 consecutive days every 3 weeks for up to 8 cycles, and 
were stratified by stage (ie, IIA or IIB). All patients 
were monitored for toxicity and clinical efficacy, the latter 
being assessed by changes in disease burden and quality of 
life measurements.
The study enrolled 71 patients, and 48 (68%) had 
advanced disease (stage IIB or greater). Overall, 21 (30%) 
of the 71 patients with CTCL treated with denileukin diftitox 
had an objective response (20% partial response and 10% 
complete response). There was no difference in the overall 
response rate between the 9 or 18 µg/kg/day cohorts; how-
ever, a subset analysis of patients with stage IIB disease or 
higher, showed a trend towards higher response (P = 0.07). 
Quality-of-life improvements following denileukin diftitox 
therapy were seen both in responders and in nonresponders, 
and this was mainly a result of clinical improvements in 
pruritus in 68% of the patients. In patients who responded, 
the use of rescue medications such as topical steroids or oral 
antihistamines was also decreased.
Fifty of the 71 patients were classified as nonresponders; 
however only 2 (3%) of patients had progression of disease. 
The remainder of the patients had stable disease (32%), or 
withdrew due to intolerance to the therapy (35%) before 
they could be assessed. The authors commented that even 
in patients who were classified as stable disease, had a signifi-
cant initial response to therapy.
It is again noteworthy that the majority of patients had 
detectable levels of antidenileukin diftitox and/or anti-
IL2 after treatment with denileukin diftitox, however, the 
presence of these antibodies did not impair the response 
to treatment. Curiously, higher antidenileukin diftitox anti-
body levels were associated with a lower incidence of rash, 
hypoalbuminemia, and transaminase elevations, but did not 
correspond to infusion-related reactions. It is thought that 
the development of antibodies to denileukin diftitox may 
contribute to the increase in clearance of denileukin diftitox 
that was observed by cycle 3.
Negro-Vilar et al reported preliminary results of a 
placebo-controlled phase III trial of up to 8 cycles of deni-
leukin diftitox in 144 patients with stage IA to III disease, the 
largest CTCL trial to date.32 Patients with at least 3 prior treat-
ments were included. Overall response rates for the placebo, 
low-dose (9 µg/kg), and high-dose (18 µg/kg) treatment 
arms were 16%, 38%, and 49%, respectively, with median 
times to progression of 4, 26, and greater than 32 months, 
respectively. In an unpublished meta-analysis of three 
phase III clinical trials of denileukin diftitox for the treatment 
of CTCL, Negro-Vilar also reported there was no correlation 
between CD25 expression and response.33
Denileukin diftitox in combination 
treatments
Since the expression of IL2R has been largely thought to be 
important in T-cell targeting of denileukin diftitox, strategies 
to upregulate IL2R expression have been explored. Retinoids 
have demonstrated efficacy in the treatment of MF/SS and 
have antiproliferative, antiangiogenic, immune-modulating,  Cancer Management and Research 2010:2 57
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and cellular effects.34 In vitro studies demonstrated that the 
retinoid × receptor (RXR) retinoid, bexarotene, at biologically 
relevant concentrations of 10(-6) M to 10(-8) M, upregulated 
both the p55 and p75 subunits o  f  the IL2R and the susceptibility 
of T-cell leukemia cells to denileukin diftitox.35,36 In a phase I 
dose-escalation trial, denileukin diftitox 18 µg/kg × 3 days 
was administered in combination with oral bexarotene 
(75 to 300 mg/day) every 21 days to patients with relapsed 
or refractory MF/SS.36 The overall response rate was 70%, 
and responders included patients who had stable disease or 
no response on denileukin diftitox alone. CD25 expression 
on CD4+ cells was measured by immunohistochemistry or 
flow cytometry at baseline and after 7 days of bexarotene. 
Modulation of the IL2R was seen with doses of bexarotene 
150 mg daily and higher. All 4 patients who achieved a CR 
and 1 of 3 patients who achieved a PR had evidence of 50% 
upregulation after bexarotene treatment. The combination 
was tolerated well with no overlapping adverse events.
Arginine butyrate is a histone deacetylase (HDAC) 
inhibitor that also has been shown to increase IL2R-beta 
(CD122) subunit gene and protein expression.37 While low 
dose arginine butyrate showed no growth inhibitor effect of 
its own, combination studies with denileukin diftitox in vitro 
showed an increase in cytotoxicity. Since HDAC inhibitors 
are clinically active compounds in CTCL, combination 
therapies to test potential synergism with denileukin diftitox 
are warranted.
Improvements of quality of life
CTCL affects numerous dimensions of quality of life (QOL) 
due to relentless painful, pruritic and disfiguring lesions. 
QOL was evaluated as a secondary endpoint in heavily pre-
treated advanced and/or recurrent CTCL patients enrolled 
in the multicenter randomized phase III trial of denileukin 
diftitox by Olsen et al using the Functional Assessment of 
Cancer Therapy-General (FACT-G) scale.31,38 FACT-G was 
developed to measure health-related QOL in patients with 
cancer.39 This tool measures four domains of quality of life: 
physical, functional, social and emotional well-being, as well 
as patient-physician relationships. The physical well-being 
scale assesses energy level, pain and side effects of treat-
ment. Relationships with family and friends are addressed 
in the social well-being subscale. The emotional well-being 
subscale evaluates for anxiety and depression. The ability 
to sleep, work and participate in desired leisure activities 
are addressed in the functional well-being subscale. The 
relationship-with-physician subscale measures satisfaction 
with interaction and care provided by the physician.
In the study by Olsen et al the 71 patients who received 
denileukin diftitox were administered the FACT-G question-
naire at baseline prior to the start of therapy and prior to 
each treatment cycle. In addition, along with each FACT-G 
measurement, patients were asked to rate the appearance 
of their skin on a 7-point global severity scale. Because the 
symptom of pruritus was not specifically addressed in the 
physical well-being subscale of the FACT-G, patients were 
also asked to rate severity of pruritus on a 10-cm visual 
analog scale.38
In the 21 patients who achieved a complete or partial 
response to denileukin diftitox, the FACT-G and most indi-
vidual subscale scores improved during the study period 
reaching statistical significance by cycle 3 (P  0.05) and 
were significantly higher than scores of non-responders at 
the completion of the study (P  0.041).38 Additionally for 
responders, skin and pruritus severity scores showed sig-
nificant improvement at study end compared with baseline 
measurements. Nonresponders also showed brief improve-
ment in QOL while receiving denileukin diftitox, but this 
declined with the discontinuation of therapy.
Management of toxicities
Overall, the most commonly reported adverse events (AE) 
in the pivotal study by Olsen et al were flu-like symptoms 
(85%). These reactions generally improved with an anti-
pyretic, antiemetic, and/or antidiarrheal treatment. Other 
common AEs were acute hypersensitivity-type reactions, 
asthenia, nausea/vomiting (which led to dehydration in some 
patients), and infectious complications. The frequency of 
hypersensitivity reactions that occurred during or within 
24 hours of drug administration was 60% and improved with 
steroid, antihistamine, and acetaminophen pre-medication 
prior to subsequent cycles. It should be noted that routine 
pre-medication was prohibited in this study. In clinical use, 
the routine use of pre-medication does reduce this complica-
tion significantly, however. The incidence of serious infusion 
reactions across 3 clinical studies (n = 234 patients) was 
8.1%. Various pre-medication protocols have been proposed 
including one by Dang et al40 and consists of dexamethasone 
4 mg iv, diphenhydramine 25 to 50 mg iv, and acetaminophen 
650 mg po.
Vascular leak syndrome was reported in 25% of patients 
and was defined as hypotension, hypoalbuminemia, and 
peripheral edema. The vascular leak syndrome occurred 
within the first 14 days of treatment and was usually self-
limited. Patients responded well to judicious use of diuretics 
for edema, and slow hydration for hypotension. Serum  Cancer Management and Research 2010:2 58
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albumin 3 g/dL and pre-exisiting edema seemed to predict 
the development of vascular leak syndrome. The authors 
recommend an additional clinical evaluation of the patient 
for changes in weight and fluid shifts at least one time within 
the first 10 days after treatment begins. The US Food and 
Drug Administration boxed warning states that denileukin 
diftitox should only be administered in a facility equipped 
and staffed for cardiopulmonary resuscitation.
All adverse events in the pivotal phase III study were 
most severe during the first two cycles of treatment and 
then diminished significantly. Hepatic transaminase levels 
were commonly elevated, with 19% of patients experiencing 
grade 3–4 elevations. Most elevations were observed during 
the first therapy cycle and diminished during all subsequent 
cycles. Mild elevations in creatinine were noted rarely and 
were reversible. There was no significant bone marrow sup-
pression, although lymphocyte counts fluctuated transiently 
in 70% of patients. Infections were reported but were con-
sidered typical infections of CTCL patients, and not related 
to denileukin diftitox.
Postmarketing reports of serious events include thyrotoxi-
cosis as reported by Ghori et al41 Clinical thyrotoxicosis was 
described in 8 patients treated at a single center; 4 patients 
developed thyrotoxicosis within days of the first cycle of 
denileukin diftitox therapy, and 4 patients after the second 
cycle. Symptoms of tremor, tachycardia, nausea, diarrhea, 
and weight loss should trigger suspicion of this condition 
which resolves after drug discontinuation. Subsequent 
clinical hypothyroidism developed in 5 of these patients 
requiring thyroid replacement therapy. Loss of visual acuity 
and color vision is another black box warning and may have 
to do with retinal changes, however the mechanism of this 
rare phenomenon is not known.42 Lastly, rhabdomyolysis 
has been reported in the context of severe vascular leak,43 
and the authors also have independently experienced this 
complication in two of their patients.
Conclusion
Denileukin diftitox has made great strides in the treatment 
of CTCL since its development 20 years ago. The reported 
response rates range from 30% to 50%, and treatment defi-
nitely improves the quality of life of these patients. However, 
some questions still remain.
The optimal time to use denileukin diftitox is not well 
defined. The toxicity profile and unfavorable schedule of 
administration have prevented its use as upfront treatment, 
however, denileukin diftitox may be more effective if used 
earlier in the course of the disease. While the initial response 
rate of denileukin diftitox was 38% in early-stage CTCL, the 
median number of prior treatments was five. In less heavily 
treated patients, however, the response rate was considerably 
higher, 63% and 48%, for early and late stage CTCL, respec-
tively. This suggests that the response rate may be higher in 
patients who are treated earlier in the course of their disease.
We are only now beginning to understand how to utilize 
denilekin diftitox in combination therapy. A combination trial 
of denileukin diftitox with bexarotene has shown increased 
activity over monotherapy. Due to non-overlapping toxicity 
profiles, denileukin diftitox has also been successfully been 
combined with CHOP (cyclophosphamide, doxorubin, vin-
cristine and prednisone) for peripheral T-cell lymphoma, sug-
gesting that chemotherapy combinations that incorporate this 
immunotoxin may eventually have a place in the treatment 
of advanced CTCL. It would also be useful to predict which 
patients would benefit most from treatment with denileukin 
diftitox. Initally, it was thought that the presence of CD25 
was required for entry of the drug into the malignant T-cells, 
however, recent evidence has shown durable responses in 
patients with CD25- disease. Regardless of these limitations, 
this unique immunotoxin has proven itself effective for the 
treatment of CTCL, a chronic disease with considerable 
morbidity and mortality.
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